1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Martín M, Rodriguez-Lescure A, Reboredo C, Chen E, Ruiz-Borrego M, Santaballa Bertran A, Rodríguez CA, Martinez Jañez N, Alba E, Tran K, Pelaez Fernandez I, Álvarez I, Seguí MA, De la Cruz A, Valero V, Antón-Torres A, Andrés R, Amillano K, Ponce-Lorenzo JJ, Dominguez Fernandez S, Herranz J, Rincon R, Caballero R, Guerrero-Zotano A, Rojo F, Symmans WF.

    Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

    CLINICAL CANCER RESEARCH . : .

    [doi:10.1158/1078-0432.CCR-26-0177]

  • Molina-Cerrillo J, Alonso-Gordoa T.

    Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

    EUROPEAN UROLOGY . : .

    [doi:10.1016/j.eururo.2026.04.007]

  • Pernas S, Forns X, Martínez-Sáez O, Andrade R, Amador A, López-Miranda E, Bermejo B, Mateos B, Cejuela M, Villanueva MJ, Ozores PP, Riveiro-Barciela M, Bellet M.

    Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

    Clinical & Translational Oncology . : .

    [doi:10.1007/s12094-026-04369-7]

  • Araujo-Castro M, Casals G, Goi J, Lamas C, García Cano AM, Rebollo-Román Á, Morales M, Sebastian-Valles F, Marazuela M, Hernández-Alfonso J, Ruz-Caracuel I, Hanzu FA.

    Impact of the Cosecretion of Cortisol on Surgical Outcomes and in the Urinary Steroid Profile in Primary Aldosteronism.

    Endocrine Practice . : .

    [doi:10.1016/j.eprac.2026.05.023]

  • Matheu G, Bermejo-Peréz MJ, Escudero-García N, Garcia-Duran C, Gatius-Caldero S, Guerra-Alía E, López-Agullo S, Romero I, Yange G, Barretina-Ginesta MP.

    Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.

    Clinical & Translational Oncology . : .

    [doi:10.1007/s12094-026-04335-3]

  • Donato S, Herrera-Martínez AD, Jacome-Gaibor VA, Ruz-Caracuel I, Toledo R, Araujo-Castro M.

    Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.

    Endocrine Connections . : .

    [doi:10.1530/EC-26-0501]

  • Rescigno P, Taha T, Fita MJ, Matthews D, Fujita K, Lolli C, DI Costanzo F, Juárez A, Ürün Y, Yazgan SC, Li H, Facchini G, Quiroga MN, Sammarco E, Bögemann M, Santini D, Baranseh J, Roviello G, Kopp RM, Fiala O, Büttner T, Carrozza F, Ansari J, Tural D, Conteduca V, Molina-Cerrillo J, Alonso-Gordoa T, Bourlon MT, Palacios GA, Paolieri F, Zgura A, DI Rocco R, Lacerenza LG, Matrana MR, Martignetti A, Massari F, Soares A, Monteiro FS, Bastos DA, Gaughan L, Wenzel M, Mandel P, Banna GL, Santoni M.

    Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

    Minerva Urology and Nephrology . : .

    [doi:10.23736/S2724-6051.26.06453-0]

  • Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A.

    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

    ESMO Open . 11(8): 108330-108330.

    [doi:10.1016/j.esmoop.2026.108330]

  • Barretina-Ginesta MP, Madariaga A, Barahona Orpinell M, Gallego A, Guerra Alía EM, Matias-Guiu X, Sanchez Heras AB, Casla-Barrio S, Castaño F, Gonzalez Concepción M, Navarro López M, Hierro Racionero C, Ruz Torres M, Gaba García L.

    Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care.

    Clinical & Translational Oncology . : .

    [doi:10.1007/s12094-026-04467-6]

  • Iglesias Álvarez G, Capdevila J, Garcia-Carbonero R, Jimenez-Fonseca P, Benavent M, Vicente MÁ, Llanos M, López C, Alonso V, García-Centeno R, Crespo G, Alonso-Gordoa T, García Paredes B, Sevilla I, Custodio A, Páez D, Segura Á, Gallego J, San Roman M, García-Álvarez A, Alonso Álvarez B, Cacho Lavín JD, Lamarca A, Cano JM, González Florez E, Gómez D, Castaño Á, Carmona-Bayonas A.

    Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

    NEUROENDOCRINOLOGY . : 1-16.

    [doi:10.1159/000552234]